These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21697654)

  • 1. Development of an Fn14 agonistic antibody as an anti-tumor agent.
    Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB
    MAbs; 2011; 3(4):362-75. PubMed ID: 21697654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
    Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB
    Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.
    Salzmann S; Seher A; Trebing J; Weisenberger D; Rosenthal A; Siegmund D; Wajant H
    J Biol Chem; 2013 May; 288(19):13455-66. PubMed ID: 23532848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TWEAK signals through JAK-STAT to induce tumor cell apoptosis.
    Chapman MS; Wu L; Amatucci A; Ho SN; Michaelson JS
    Cytokine; 2013 Jan; 61(1):210-7. PubMed ID: 23107828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.
    Chopra M; Brandl A; Siegmund D; Mottok A; Schäfer V; Biehl M; Kraus S; Bäuerlein CA; Ritz M; Mattenheimer K; Schwinn S; Seher A; Grabinger T; Einsele H; Rosenwald A; Brunner T; Beilhack A; Wajant H
    Blood; 2015 Jul; 126(4):437-44. PubMed ID: 26012567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.
    Aronin A; Amsili S; Prigozhina TB; Tzdaka K; Rachmilewitz J; Shani N; Tykocinski ML; Dranitzki Elhalel M
    PLoS One; 2013; 8(10):e77050. PubMed ID: 24130833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.
    Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG
    Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.
    Prigozhina TB; Szafer F; Aronin A; Tzdaka K; Amsili S; Makdasi E; Shani N; Dranitzki Elhalel M
    Cancer Lett; 2017 Aug; 400():99-109. PubMed ID: 28455246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.
    Zaitseva O; Hoffmann A; Löst M; Anany MA; Zhang T; Kucka K; Wiegering A; Otto C; Wajant H
    Front Immunol; 2023; 14():1194610. PubMed ID: 37545514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
    Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL
    Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
    Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA
    Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).
    Fick A; Lang I; Schäfer V; Seher A; Trebing J; Weisenberger D; Wajant H
    J Biol Chem; 2012 Jan; 287(1):484-495. PubMed ID: 22081603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.
    Nakayama M; Ishidoh K; Kojima Y; Harada N; Kominami E; Okumura K; Yagita H
    J Immunol; 2003 Jan; 170(1):341-8. PubMed ID: 12496418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.
    Dhruv H; Loftus JC; Narang P; Petit JL; Fameree M; Burton J; Tchegho G; Chow D; Yin H; Al-Abed Y; Berens ME; Tran NL; Meurice N
    J Biol Chem; 2013 Nov; 288(45):32261-32276. PubMed ID: 24056367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system.
    Echeverry R; Wu F; Haile WB; Wu J; Yepes M
    J Neuroinflammation; 2012 Mar; 9():45. PubMed ID: 22394384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
    Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
    Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.
    Sanz AB; Sanchez-Niño MD; Carrasco S; Manzarbeitia F; Ruiz-Andres O; Selgas R; Ruiz-Ortega M; Gonzalez-Enguita C; Egido J; Ortiz A
    PLoS One; 2012; 7(10):e47440. PubMed ID: 23077618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules.
    Brown SA; Hanscom HN; Vu H; Brew SA; Winkles JA
    Biochem J; 2006 Jul; 397(2):297-304. PubMed ID: 16526941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
    Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG
    J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.
    Xia Y; Campbell SR; Broder A; Herlitz L; Abadi M; Wu P; Michaelson JS; Burkly LC; Putterman C
    Clin Immunol; 2012 Nov; 145(2):108-21. PubMed ID: 22982296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.